Navigation Links
Pharmos Issues Business Update on Dextofisopam Trial and Financing
Date:4/2/2009

toimmune disorders. The Company's lead product in development, dextofisopam, is undergoing Phase 2b testing in IBS patients. Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders. These are available for licensing / partnering. On February 18, 2009, Pharmos Corporation and its Israeli subsidiary, Pharmos Ltd., entered into an Asset Purchase Agreement with Reperio Pharmaceuticals Ltd. for the sale of the patent rights and technical know-how related to the compound known as PRS-639,058 and certain follow-on molecules.

Safe Harbor Statement

Statements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.


'/>"/>
SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
2. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
3. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
4. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
7. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
9. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
10. European Unions CHMP Issues Positive Opinion on Sugammadex
11. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 Reportbuyer.com ... Global Markets and Technologies for Molecular Imaging ... STUDY GOALS AND OBJECTIVES The objectives of ... at molecular imaging devices used for diagnostic purposes, ... market and all possible market segments as well ...
(Date:9/2/2014)... 2, 2014 Reportbuyer.com has added a ... Global Markets for Services and Devices ... Bariatric surgery or weight loss surgery is a ... processes that deal with the surgical treatment of ... (endoluminal) and performed in both open and laparoscopic ...
(Date:9/2/2014)... , Sept. 2, 2014 Astellas has appointed ... intellectual property (IP) in the Americas. Kellerman will report ... & general counsel at Astellas. In his new role, ... partner with the business and manage the region,s intellectual ... "I am very pleased to welcome Jim ...
Breaking Medicine Technology:Global Markets and Technologies for Molecular Imaging Devices 2Global Markets and Technologies for Molecular Imaging Devices 3Global Markets and Technologies for Molecular Imaging Devices 4Global Markets and Technologies for Molecular Imaging Devices 5Global Markets and Technologies for Molecular Imaging Devices 6Global Markets and Technologies for Molecular Imaging Devices 7Global Markets and Technologies for Molecular Imaging Devices 8Global Markets and Technologies for Molecular Imaging Devices 9Global Markets and Technologies for Molecular Imaging Devices 10Global Markets and Technologies for Molecular Imaging Devices 11Global Markets and Technologies for Molecular Imaging Devices 12Global Markets and Technologies for Molecular Imaging Devices 13Global Markets and Technologies for Molecular Imaging Devices 14Global Markets and Technologies for Molecular Imaging Devices 15Global Markets and Technologies for Molecular Imaging Devices 16Global Markets and Technologies for Molecular Imaging Devices 17Global Markets and Technologies for Molecular Imaging Devices 18Global Markets and Technologies for Molecular Imaging Devices 19Global Markets and Technologies for Molecular Imaging Devices 20Global Markets and Technologies for Molecular Imaging Devices 21Global Markets and Technologies for Molecular Imaging Devices 22Global Markets and Technologies for Molecular Imaging Devices 23Global Markets and Technologies for Molecular Imaging Devices 24Global Markets and Technologies for Molecular Imaging Devices 25Bariatric Surgery: Global Markets for Services and Devices 2Bariatric Surgery: Global Markets for Services and Devices 3Bariatric Surgery: Global Markets for Services and Devices 4Bariatric Surgery: Global Markets for Services and Devices 5Bariatric Surgery: Global Markets for Services and Devices 6Bariatric Surgery: Global Markets for Services and Devices 7Bariatric Surgery: Global Markets for Services and Devices 8Bariatric Surgery: Global Markets for Services and Devices 9Bariatric Surgery: Global Markets for Services and Devices 10Bariatric Surgery: Global Markets for Services and Devices 11Bariatric Surgery: Global Markets for Services and Devices 12
... NATICK, Mass. and BARCELONA, Spain, May 20 Boston ... results from an analysis of economic and quality of ... SYNTAX trial. The results found that percutaneous coronary ... System was consistently associated with fewer patient hospital days ...
... suggest pirfenidone may provide meaningful clinical benefit in IPF ... safety reported -- Conference Call and Webcast at 9 ... 19 InterMune, Inc. (Nasdaq: ITMN ) ... studies evaluating pirfenidone in patients with idiopathic pulmonary fibrosis ...
Cached Medicine Technology:SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 2SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 3SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 5Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 2Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 3Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 4Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 5Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 6Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 7Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 8Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 9Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 10Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 11Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 12
(Date:9/2/2014)... (PRWEB) September 02, 2014 TCG, a leading ... Inc. 5000 as one of the fastest-growing companies in America ... time total. TCG was previously recognized in 2013, 2012, 2011, ... TCG’s revenue has grown 86% from 2010 to 2013, ranking ... fastest growing businesses in America - up 635 spots from ...
(Date:9/2/2014)... Los Angeles, CA (PRWEB) September 02, 2014 ... an article on its website titled “Why You Should ... more than 80 percent of the global population breathes ... droplets and particles of pollution lodge in the skin’s ... the body’s natural barrier to free radicals that may ...
(Date:9/2/2014)... can lay the groundwork for their own spread throughout ... send out tumor-welcoming signals, according to a new report ... 2 issue of Nature Communications , the researchers ... of so-called signaling molecules released by breast cancer cells. ... lungs and lymph nodes to produce proteins called CCL5 ...
(Date:9/2/2014)... Kathleen Doheny HealthDay Reporter ... epidemic is a driving force behind the rising rates of ... looked at data from five national surveys spanning from 1976 ... over time could be explained by factors such as changing ... The investigators found that the prevalence of diabetes in men ...
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- A leading group ... of the major form of advanced breast cancer. ... to drugs that target the HER2 protein, the American ... news release. Almost 80 percent of women ... noted. "In releasing this guideline, our aim is ...
Breaking Medicine News(10 mins):Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2
... To help continue its internationally recognized work in ... has awarded Mayo Clinic a $1 million gift, pledged over ... Alzheimer,s and Parkinson,s diseases , is the ... VIDEO ALERT: Additional audio and video resources, ...
... ANGELES (March 22, 2011) When physical therapy and drugs fail ... spinal fusion surgery as a last resort, but two new ... are involved, artificial disc replacement may give better long-term results ... were 49 percent lower, and four years out from surgery, ...
... asthma patients are in part caused by the naturally ... cells called fibroblasts, according to a study conducted by ... effort by researchers to better understand the processes that ... difficulties in patients with asthma.,The findings were published online ...
... planned NHS and welfare reforms, and their use of ,nudge, ... the end of the nineteenth century, according to studies by ... been published in the Lancet . Dr Kim ... history, is his second in the Lancet within a year ...
... members providing care to older adults in the United ... associations. When older adults are hospitalized and discharged, their ... and how they will receive care. A University of ... will intensify with increasing demands for health care and ...
... limited number of toys showed more improvement in their ... community-based treatments. The report is the first ... Than Words for children younger than 2 showing ... enough and treated with the right behavioral therapy, autism ...
Cached Medicine News:Health News:Gift will allow Mayo researchers to explore cause of dementia in the elderly 2Health News:Gift will allow Mayo researchers to explore cause of dementia in the elderly 3Health News:For back, neck pain, artificial disc replacement has cost, outcome advantages over fusion surgery 2Health News:For back, neck pain, artificial disc replacement has cost, outcome advantages over fusion surgery 3Health News:Protein associated with allergic response causes airway changes in asthma patients 2Health News:Protein associated with allergic response causes airway changes in asthma patients 3Health News:Report indicates that 'new' welfare reforms hark back to Victorians 2Health News:Gaps in health care limit options for older adults, MU expert says 2Health News:Interest in toys predicts effectiveness of autism treatment in toddlers 2Health News:Interest in toys predicts effectiveness of autism treatment in toddlers 3
... Use Articulating linear stapler ... ,The Auto Suture™ ROTICULATOR™ ... ROTICULATOR™ 55 single use ... abdominal, gynecological, pediatric and ...
... Linear Staplers deliver two staggered rows of titanium ... may be reloaded up to three times for ... heavy wire staples for thick tissue. The TLV ... ,Benefits include: , Parallel jaw closure ensures ...
... Use reloadable linear stapler ... (DST™) titanium staples., ... Reloadable staplers has application ... and thoracic surgical procedures ...
... GIA™ 75-.060 single use surgical stapler ... LACTOMER™ absorbable copolymer staples and simultaneously ... double rows., ,The Auto Suture™ ... stapler has application in surgical procedures ...
Medicine Products: